Dmitry Balyasny’s Matinas BioPharma MTNB Stock Holding History

Dmitry Balyasny’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,982	Closed	-$63K	–	3064
2022 Q3	$63K	Buy	+1,982	New	+$77.8K	﹤0.01%	2452

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Dmitry Balyasny's MTNB Position: Q4 2022 in Review

Dmitry Balyasny sold out of Matinas BioPharma (MTNB) in Q4 2022, closing a stake of 1,982 shares — an estimated $63K sold.

Dmitry Balyasny first reported a position in MTNB in Q3 2022 and held it in 1 quarter. The position peaked at $63K in Q3 2022. 57 funds tracked by Wall St. Rank hold MTNB as of Q4 2022.

Dmitry Balyasny reported no remaining Matinas BioPharma position as of Q4 2022 after selling out during the quarter.
Dmitry Balyasny sold 1,982 Matinas BioPharma shares in Q4 2022, an estimated $63K.
Dmitry Balyasny first reported a position in Matinas BioPharma in Q3 2022 and held it in 1 quarter.
Dmitry Balyasny's Matinas BioPharma position peaked at $63K in Q3 2022.
57 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.